Comparable results were obtained for AD patients and healthy elderly individuals, and for all three of the β-amyloids used: 1–42, 1–40 and 25–35, all of which were enhancing the proliferative response of CD4+CD28+ lymphocytes to anti-CD3 antibody. This evidence concerns the gene CD4 and Alzheimer disease.